MCID: MYS005
MIFTS: 57

Myositis malady

Categories: Muscle diseases, Neuronal diseases, Rare diseases, Infectious diseases

Aliases & Classifications for Myositis

Summaries for Myositis

MedlinePlus : 41 myositis means inflammation of the muscles that you use to move your body. an injury, infection, or autoimmune disease can cause it. two specific kinds are polymyositis and dermatomyositis. polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. dermatomyositis causes muscle weakness, plus a skin rash. other symptoms of myositis may include fatigue after walking or standing tripping or falling trouble swallowing or breathing doctors may use a physical exam, lab tests, imaging tests and a muscle biopsy to diagnose myositis. there is no cure for these diseases, but you can treat the symptoms. polymyositis and dermatomyositis are first treated with high doses of a corticosteroid. other options include medications, physical therapy, exercise, heat therapy, assistive devices, and rest. nih: national institute of neurological disorders and stroke

MalaCards based summary : Myositis, also known as inflammatory disorder of muscle, is related to lyme disease and inclusion body myositis, and has symptoms including proximal muscle weakness, back pain and muscle cramp. An important gene associated with Myositis is HARS (Histidyl-TRNA Synthetase), and among its related pathways/superpathways are Neuroscience and tRNA Aminoacylation. The drugs Simvastatin and Tenofovir have been mentioned in the context of this disorder. Affiliated tissues include testes, bone and t cells, and related phenotypes are Decreased viability and behavior/neurological

Disease Ontology : 12 A myopathy characterized by muscle inflammation.

Wikipedia : 71 Myositis is inflammation or swelling of the muscles. Injury, medicines, infection, or an immune disorder... more...

Related Diseases for Myositis

Diseases in the Myositis family:

Bacterial Myositis Viral Myositis

Diseases related to Myositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 349)
id Related Disease Score Top Affiliating Genes
1 lyme disease 29.2 CAPN3 DMD DYSF GNE TTN
2 inclusion body myositis 12.5
3 myositis ossificans 12.2
4 focal myositis 12.1
5 myositis fibrosa 12.0
6 fibrodysplasia ossificans progressiva 12.0
7 bacterial myositis 12.0
8 viral myositis 12.0
9 infective myositis 12.0
10 fungal myositis 12.0
11 idiopathic eosinophilic myositis 11.9
12 overlap myositis 11.9
13 granulomatous myositis 11.9
14 pyomyositis 11.8
15 juvenile overlap myositis 11.8
16 idiopathic inflammatory myopathy 11.8
17 dermatomyositis 11.6
18 polymyositis 11.2
19 antisynthetase syndrome 11.1
20 orbital plasma cell granuloma 10.8
21 muscle disorders 10.8
22 foot drop 10.8
23 osseous heteroplasia, progressive 10.7
24 childhood type dermatomyositis 10.7
25 epidemic pleurodynia 10.7
26 immune-mediated necrotizing myopathy 10.7
27 adrenal cortex disease 10.3 DYSF PIK3C2A
28 cerebral hemorrhage 10.3 CAPN3 DYSF
29 rippling muscle disease 10.3 DYSF MSTN
30 macrophagic myofasciitis 10.3
31 congenital heart defects, multiple types, 3 10.3 CAPN3 DYSF TTN
32 myopathy, early-onset, with fatal cardiomyopathy 10.3 CAPN3 TTN
33 autosomal dominant limb-girdle muscular dystrophy type 1c 10.3 CAPN3 DYSF TTN
34 vulvar vestibulitis syndrome 10.3 MB PIK3C2A
35 silent myocardial infarction 10.3 MAPT MB PIK3C2A
36 charcot-marie-tooth disease, type 2b2 10.3 CAPN3 DYSF TTN
37 spinocerebellar ataxia 11 10.3 CAPN3 DYSF TTN
38 mammary paget's disease 10.3 NCAM1 PIK3C2A TTN
39 hypereosinophilic syndrome, idiopathic, resistant to imatinib 10.3 CAPN3 DYSF TTN
40 osteogenesis imperfecta with opalescent teeth, blue sclerae and wormian bones but without fractures 10.3 DYSF MSTN
41 myopathy 10.2
42 myopathy, distal, tateyama type 10.2 CHKB MB PIK3C2A
43 craniosynostosis with radiohumeral fusions and other skeletal and craniofacial anomalies 10.2 CAPN3 CHKB DYSF
44 lumbar malsegmentation short stature 10.2 DMD DYSF
45 chorea gravidarum 10.2 CHKB MB PIK3C2A
46 papillary pattern testicular yolk sac tumor 10.2 MB PIK3C2A
47 infiltrating ureter transitional cell carcinoma 10.2 CHKB MB PIK3C2A
48 inferolateral myocardial infarct 10.2 CHKB PIK3C2A
49 short stature, developmental delay, and congenital heart defects 10.2 CHKB MB
50 cardiomyopathy, dilated, 1u 10.2 APP BACE1 MAPT

Graphical network of the top 20 diseases related to Myositis:



Diseases related to Myositis

Symptoms & Phenotypes for Myositis

Human phenotypes related to Myositis:

32
id Description HPO Frequency HPO Source Accession
1 myositis 32 HP:0100614
2 proximal muscle weakness 32 HP:0003701

UMLS symptoms related to Myositis:


back pain, muscle cramp, muscle rigidity, muscle spasticity, myoclonus, sciatica, torticollis, muscle weakness, myalgia

GenomeRNAi Phenotypes related to Myositis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.66 PIK3C2A
2 Decreased viability GR00221-A-1 9.66 GNE PIK3C2A CHKB
3 Decreased viability GR00221-A-2 9.66 PIK3C2A TTN CHKB
4 Decreased viability GR00221-A-3 9.66 CHKB GNE
5 Decreased viability GR00221-A-4 9.66 DYSF GNE PIK3C2A TTN CHKB
6 Decreased viability GR00240-S-1 9.66 PIK3C2A
7 Decreased viability GR00301-A 9.66 CHKB DYSF
8 Decreased viability GR00342-S-1 9.66 PIK3C2A TTN
9 Decreased viability GR00342-S-2 9.66 PIK3C2A
10 Decreased viability GR00342-S-3 9.66 PIK3C2A TTN
11 Decreased hepcidin::fluc mRNA expression GR00253-A 9.61 AARS APP BACE1 DMD DYSF MSTN

MGI Mouse Phenotypes related to Myositis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 AARS APP BACE1 CHKB DMD DYSF
2 cellular MP:0005384 10.15 AARS APP BACE1 BACE2 DMD IFIH1
3 growth/size/body region MP:0005378 10.13 IFIH1 MAPT MB MSTN PIK3C2A TTN
4 homeostasis/metabolism MP:0005376 10.07 APP BACE1 CAPN3 CHKB DMD DYSF
5 cardiovascular system MP:0005385 10.06 AARS CAPN3 DMD GNE MAPT MB
6 mortality/aging MP:0010768 10 NCAM1 PIK3C2A TTN AARS APP BACE1
7 muscle MP:0005369 9.73 AARS APP BACE1 CAPN3 CHKB DMD
8 no phenotypic analysis MP:0003012 9.17 APP BACE1 CAPN3 DMD DYSF MAPT

Drugs & Therapeutics for Myositis

Drugs for Myositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 2,Phase 3 79902-63-9 54454
2
Tenofovir Approved, Investigational Phase 4 147127-20-6 464205
3
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
4
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
5
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
6
Benzocaine Approved Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
7
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
8
Liraglutide Approved Phase 4 204656-20-2
9 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3
10
Pirfenidone Investigational Phase 4 53179-13-8 40632
11 Rosuvastatin Calcium Phase 4 147098-20-2
12 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
13 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
14 Hormones Phase 4,Phase 3,Phase 2,Phase 1
15 Vaccines Phase 4
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
18 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3
19 Hypolipidemic Agents Phase 4,Phase 2
20 Anti-HIV Agents Phase 4
21 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
23 Anticholesteremic Agents Phase 4,Phase 2
24 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Lipid Regulating Agents Phase 4,Phase 2
26 Antimetabolites Phase 4,Phase 3,Phase 2
27 Anti-Retroviral Agents Phase 4
28 Reverse Transcriptase Inhibitors Phase 4
29 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antiviral Agents Phase 4,Phase 1
31 Calcium, Dietary Phase 4,Phase 3,Early Phase 1
32 Ubiquinone Phase 4,Phase 2,Phase 3
33
Angiotensin II Phase 4 68521-88-0, 11128-99-7 65143 172198
34 insulin Phase 4,Phase 1
35 beta-endorphin Phase 4,Phase 2
36
Olmesartan medoxomil Phase 4 144689-63-4 130881
37 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
38
protease inhibitors Phase 4
39 Serine Proteinase Inhibitors Phase 4
40 Adrenocorticotropic Hormone Phase 4,Phase 2
41 HIV Protease Inhibitors Phase 4
42 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
43 Trace Elements Phase 4,Phase 2,Phase 3
44 Vasoconstrictor Agents Phase 4
45 Angiotensin II Type 1 Receptor Blockers Phase 4
46 Angiotensin Receptor Antagonists Phase 4
47 Angiotensinogen Phase 4
48 Vitamins Phase 4,Phase 2,Phase 3
49 Insulin, Globin Zinc Phase 4,Phase 1
50 Antihypertensive Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 150)
id Name Status NCT ID Phase
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4
2 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4
5 Angiotensin II Blockade and Inflammation in Obesity Completed NCT01684748 Phase 4
6 Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being Completed NCT02255682 Phase 4
7 Stop Atherosclerosis in Native Diabetics Study Completed NCT00147251 Phase 4
8 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4
9 Living With Statins - Interventional Exercise Study Recruiting NCT02796378 Phase 4
10 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4
11 The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans Active, not recruiting NCT02403284 Phase 4
12 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Not yet recruiting NCT02821689 Phase 4
13 Is Myopathy Part of Statin Therapy (IMPOSTER-16) Terminated NCT00127335 Phase 4
14 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Unknown status NCT00504348 Phase 2, Phase 3
15 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3
16 Arimoclomol in Sporadic Inclusion Body Myositis Completed NCT00769860 Phase 2, Phase 3
17 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3
18 Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02250443 Phase 2, Phase 3
19 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3
20 Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients Completed NCT01925209 Phase 2, Phase 3
21 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3
22 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms Completed NCT01032993 Phase 2, Phase 3
23 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3
24 Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients Completed NCT00975000 Phase 3
25 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3
26 Scleroderma: Cyclophosphamide or Transplantation (SCOT) Completed NCT00114530 Phase 2, Phase 3
27 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3
28 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3
29 Belimumab in Myositis Recruiting NCT02347891 Phase 2, Phase 3
30 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3
31 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Recruiting NCT02728752 Phase 3
32 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3
33 An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 Active, not recruiting NCT02573467 Phase 3
34 Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis Active, not recruiting NCT02481453 Phase 2, Phase 3
35 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3
36 Statins for the Early Treatment of Sepsis Unknown status NCT00528580 Phase 2
37 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2
38 Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT01423110 Phase 2
39 Alemtuzumab to Treat Sporadic Inclusion Body Myositis Completed NCT00079768 Phase 2
40 Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2
41 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2
42 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2
43 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2
44 The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers Completed NCT00805870 Phase 2
45 Methimazole to Treat Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2
46 Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2
47 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed NCT01906372 Phase 2
48 Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis Completed NCT00005571 Phase 2
49 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
50 Safety and Efficacy of BAF312 in Dermatomyositis Completed NCT02029274 Phase 2

Search NIH Clinical Center for Myositis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: myositis

Genetic Tests for Myositis

Genetic tests related to Myositis:

id Genetic test Affiliating Genes
1 Myositis 29

Anatomical Context for Myositis

MalaCards organs/tissues related to Myositis:

39
Testes, Bone, T Cells, Skin, Skeletal Muscle, Lung, Tongue

Publications for Myositis

Articles related to Myositis:

(show top 50) (show all 1922)
id Title Authors Year
1
Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients. ( 28076913 )
2017
2
Sporadic inclusion body myositis - a myodegenerative disease or an inflammatory myopathy. ( 28111778 )
2017
3
Physical function and muscle strength in sporadic inclusion body myositis. ( 28187529 )
2017
4
Henoch-SchAPnlein Purpura With Muscle Involvement, Presenting as Myositis. ( 28002161 )
2017
5
Inclusion body myositis pathogenesis: Steady progress. ( 28318035 )
2017
6
Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. ( 28283597 )
2017
7
Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. ( 28279643 )
2017
8
Fist sign in inclusion body myositis. ( 28215761 )
2017
9
Burden of Illness and Healthcare Resource Use in US Patients with sporadic Inclusion Body Myositis. ( 28493327 )
2017
10
Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis. ( 28318044 )
2017
11
Sarcoidosis: Is It a Possible Trigger of Inclusion Body Myositis? ( 28523201 )
2017
12
Association study reveals novel risk loci for sporadic inclusion body myositis. ( 28233382 )
2017
13
Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis. ( 28082622 )
2017
14
A Systematic Review and Meta-Analysis ofA Prevalence Studies of Sporadic Inclusion Body Myositis. ( 28505979 )
2017
15
Immune-array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity across the Myositis Spectrum. ( 28086002 )
2017
16
A Case of Asymptomatic Inclusion Body Myositis. ( 28221303 )
2017
17
Clinical Implications and Hospital Outcome of Immune-Mediated Myositis in Horses. ( 28044365 )
2017
18
Comparison of serum rAAV serotype-specific antibodies in patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis or GNE myopathy. ( 28042944 )
2017
19
Calcium dysregulation, functional calpainopathy, and endoplasmic reticulum stress in sporadic inclusion body myositis. ( 28330496 )
2017
20
Intrathoracic tumor of the chest wall: A case of Castleman's disease mimicking myositis of the lower extremities. ( 28074445 )
2017
21
The role of p62/SQSTM1 in sporadic inclusion body myositis. ( 28159418 )
2017
22
Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. ( 28122761 )
2017
23
Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. ( 27761751 )
2016
24
A Negative Antinuclear Antibody Does Not Indicate Autoantibody Negativity in Myositis: Role of Anticytoplasmic Antibody as a Screening Test for Antisynthetase Syndrome. ( 27909085 )
2016
25
Intra-abdominal myositis ossificans in an asymptomatic patient during closure of a Hartmann's colostomy. ( 27887014 )
2016
26
Targeting protein homeostasis in sporadic inclusion body myositis. ( 27009270 )
2016
27
A rare case of pediatric Nontraumatic Myositis Ossificans in the posterior triangle. ( 27063765 )
2016
28
Fever, Myositis, and Paralysis: Is This Inflammatory Myopathy or Neuroinvasive Disease? ( 27119037 )
2016
29
Contribution of dot-blot assay to the diagnosis and management of myositis: a three-year practice at a university hospital centre. ( 27494325 )
2016
30
Inclusion Body Myositis. ( 27922498 )
2016
31
Multicenter Registry on Inflammatory Myositis From the Rheumatology Society in Madrid, Spain: Descriptive Analysis. ( 27616211 )
2016
32
A novel ultrastructural finding in statin-exposed patients with inflammatory myositis. ( 27956275 )
2016
33
Fronto-orbital tuberculous osteomyelitis with temporalis myositis. ( 27153182 )
2016
34
Sporadic Inclusion Body Myositis Manifesting as Isolated Muscle Weakness of the Finger Flexors Three Years after Disease Onset. ( 27904121 )
2016
35
Myositis complicating benzathine penicillin-G injection in a case of rheumatic heart disease. ( 27051573 )
2016
36
Efficacy of immunosuppressive treatment in a systemic lupus erythematosus patient presenting with inclusion body myositis. ( 27048400 )
2016
37
Botulinum toxin and rehabilitation treatment in inclusion body myositis for severe oropharyngeal dysphagia. ( 27098244 )
2016
38
Focal myositis: A review. ( 27726926 )
2016
39
Diagnostic criteria for inclusion body myositis. ( 27027255 )
2016
40
Lagophthalmos and Ptosis in Inclusion Body Myositis. ( 26784549 )
2016
41
CLOSTRIDIAL PARAPROCTITIS WITH GAS GANGRENE OF FRONT-LATERAL ABDOMINAL WALLS AND NECROTIC FASCIO-MYOSITIS (CASE REPORT). ( 27770534 )
2016
42
Eosinophilic fasciitis with subjacent myositis. ( 27875630 )
2016
43
Giant cell myocarditis: a life-threatening disorder heralded by orbital myositis. ( 27009192 )
2016
44
A surprising case of inclusion body myositis with positive endomysial C5b-9 staining. ( 26659413 )
2016
45
Heterotopic mesenteric ossification of ileostomy - "intraabdominal myositis ossificans". ( 27151721 )
2016
46
Myositis ossificans traumatica (circumscripta) and return to sport: A retrospective series of 19 cases. ( 26934992 )
2016
47
Masseteric Myositis: A Unique Cause of Obstructive Sialadenitis of Parotid Gland. ( 28068299 )
2016
48
Myositis ossificans of the platysma mimicking a malignancy: a case report with review of the literature. ( 26904497 )
2016
49
Neuromuscular ultrasound in the evaluation of inclusion body myositis. ( 27797863 )
2016
50
Myositis ossificans: A rare location in the foot. Report of a case and review of literature. ( 27474831 )
2016

Variations for Myositis

Expression for Myositis

Search GEO for disease gene expression data for Myositis.

Pathways for Myositis

Pathways related to Myositis according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 12.07 APP BACE1 MAPT NCAM1
2
Show member pathways
11.7 AARS HARS NARS TARS
3 10.86 APP BACE1 MAPT
4 10.58 APP BACE1 BACE2 MAPT

GO Terms for Myositis

Cellular components related to Myositis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.65 AARS APP DYSF FBL MB NARS
2 cell surface GO:0009986 9.55 APP BACE1 BACE2 DMD NCAM1
3 cytosol GO:0005829 9.47 AARS APP CAPN3 CHKB DMD GNE
4 Z disc GO:0030018 9.43 CAPN3 DMD TTN

Biological processes related to Myositis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 translation GO:0006412 9.76 AARS HARS NARS TARS
2 muscle organ development GO:0007517 9.58 CAPN3 DMD MSTN
3 skeletal muscle tissue regeneration GO:0043403 9.48 DMD MSTN
4 response to muscle activity GO:0014850 9.43 CAPN3 MSTN
5 tRNA aminoacylation GO:0043039 9.37 AARS TARS
6 beta-amyloid metabolic process GO:0050435 9.32 BACE1 BACE2
7 negative regulation of kinase activity GO:0033673 9.26 MAPT MSTN
8 amyloid fibril formation GO:1990000 9.16 APP MAPT
9 muscle cell cellular homeostasis GO:0046716 9.13 CAPN3 DMD MSTN
10 tRNA aminoacylation for protein translation GO:0006418 8.92 AARS HARS NARS TARS

Molecular functions related to Myositis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.61 AARS CHKB GNE HARS IFIH1 NARS
2 ligase activity GO:0016874 9.56 AARS HARS NARS TARS
3 structural constituent of muscle GO:0008307 9.33 CAPN3 DMD TTN
4 ligase activity, forming aminoacyl-tRNA and related compounds GO:0016876 9.32 AARS TARS
5 aminoacyl-tRNA ligase activity GO:0004812 8.92 AARS HARS NARS TARS

Sources for Myositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....